TCM
ALXN

Tuttle Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Tuttle Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-4,907
Closed -$901K – 302
2021
Q2 		$901K Buy
+4,907
New +$842K 0.4% 104
2019
Q2 		– Sell
-15,243
Closed -$2.06M – 206
2019
Q1 		$2.06M Buy
+15,243
New +$1.9M 0.41% 79

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Tuttle Capital Management's ALXN Position: Q3 2021 in Review

Tuttle Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 4,907 shares — an estimated $901K sold.

Tuttle Capital Management first reported a position in ALXN in Q1 2019 and held it in 2 quarters. The position peaked at $2.06M in Q1 2019. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Tuttle Capital Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Tuttle Capital Management sold 4,907 Alexion Pharmaceuticals shares in Q3 2021, an estimated $901K.
  • Tuttle Capital Management first reported a position in Alexion Pharmaceuticals in Q1 2019 and held it in 2 quarters.
  • Tuttle Capital Management's Alexion Pharmaceuticals position peaked at $2.06M in Q1 2019.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Tuttle Capital Management's 13F filing for Q3 2021, filed 20 Oct 2021.